Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 3/20 | 0.55 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155649 | 0.85 | NPC1 (0.52) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14226029 | 0.83 | IL2 (0.51) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14150225 | 0.80 | STIM1 (0.70) | STIM1ORAI1TP53CDK9 | |
| SCHEMBL12156239 | 0.80 | IL2 (0.47) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12156240 | 0.78 | STIM1 (0.47) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12155667 | 0.77 | NPC1 (0.48) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12155931 | 0.77 | NPC1 (0.52) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12155891 | 0.77 | STIM1 (0.66) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12241381 | 0.75 | STIM1 (0.50) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1701649 | 0.75 | STIM1 (0.67) | STIM1ORAI1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | claimed |
| EP-4275705-B1 | PANCREATITIS TREATMENT | CALCIMEDICA INC (US) | 2025-05-14 | — | — | EP | claimed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | claimed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| CN-118871110-A | Methods and compositions for treating inflammatory lesions of the lung | 钙医学公司 | 2024-10-29 | — | — | CN | claimed |
| EP-4275705-A2 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| US-11752148-B2 | Pyrazine-containing compound | CALCIMEDICA, INC. (US) | 2023-09-12 | — | — | US | claimed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| US-20230226058-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-07-20 | — | — | US | claimed |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-04-20 | — | — | US | claimed |
| EP-4153179-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | Calcimedica, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| CN-115835878-A | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | 钙医学公司 | 2023-03-21 | — | — | CN | claimed |
| EP-4121089-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | Calcimedica, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| US-20220265645-A1 | PYRAZINE-CONTAINING COMPOUND | AVENUE CAPITAL MANAGEMENT II, L.P. | 2022-08-25 | — | — | US | claimed |
| US-11311535-B2 | Pancreatitis treatment | CALCIMEDICA, INC. (US) | 2022-04-26 | — | — | US | claimed |
| WO-2021189013-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | CALCIMEDICA, INC. (US) | 2021-09-23 | — | — | WO | claimed |
| US-20180235958-A1 | PANCREATITIS TREATMENT | AVENUE CAPITAL MANAGEMENT II, L.P. | 2018-08-23 | — | — | US | claimed |
| EP-3261641-A1 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2018-01-03 | — | — | EP | claimed |
| WO-2016138472-A1 | PANCREATITIS TREATMENT | CALCIMEDICA, INC. (US) | 2016-09-01 | — | — | WO | claimed |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4275705-B1 | PANCREATITIS TREATMENT | CALCIMEDICA INC (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | disclosed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118871110-A | Methods and compositions for treating inflammatory lesions of the lung | 钙医学公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240307384-A1 | PYRAZINE-CONTAINING COMPOUND | CALCIMEDICA, INC. | 2024-09-19 | — | — | US | disclosed |
| EP-4275705-A2 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4275705-A2 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11752148-B2 | Pyrazine-containing compound | CALCIMEDICA, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752148-B2 | Pyrazine-containing compound | CALCIMEDICA, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752148-B2 | Pyrazine-containing compound | CALCIMEDICA, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230226058-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-07-20 | — | — | US | disclosed |
| US-20230226058-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-07-20 | — | — | US | disclosed |
| US-20230226058-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-07-20 | — | — | US | disclosed |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-04-20 | — | — | US | disclosed |
| EP-4153179-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | Calcimedica, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| CN-115835878-A | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | 钙医学公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4121089-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | Calcimedica, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11439639-B2 | Pyrazine-containing compound | CALCIMEDICA, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220265645-A1 | PYRAZINE-CONTAINING COMPOUND | AVENUE CAPITAL MANAGEMENT II, L.P. | 2022-08-25 | — | — | US | disclosed |
| US-11311535-B2 | Pancreatitis treatment | CALCIMEDICA, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311535-B2 | Pancreatitis treatment | CALCIMEDICA, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220000863-A1 | PYRAZINE-CONTAINING COMPOUND | AVENUE CAPITAL MANAGEMENT II, L.P. | 2022-01-06 | — | — | US | disclosed |
| US-20220000863-A1 | PYRAZINE-CONTAINING COMPOUND | AVENUE CAPITAL MANAGEMENT II, L.P. | 2022-01-06 | — | — | US | disclosed |
| WO-2021236820-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | CALCIMEDICA, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021189013-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | CALCIMEDICA, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021189013-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | CALCIMEDICA, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11013737-B2 | Pyrazine-containing compound | CALCIMEDIA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11013737-B2 | Pyrazine-containing compound | CALCIMEDIA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10973818-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| US-10973818-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| EP-3778595-A1 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210038597-A1 | PYRAZINE-CONTAINING COMPOUND | AVENUE CAPITAL MANAGEMENT II, L.P. | 2021-02-11 | — | — | US | disclosed |
| US-20210038597-A1 | PYRAZINE-CONTAINING COMPOUND | AVENUE CAPITAL MANAGEMENT II, L.P. | 2021-02-11 | — | — | US | disclosed |
| US-20200368228-A1 | PYRAZINE-CONTAINING COMPOUND | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-11-26 | — | — | US | disclosed |
| US-20200368228-A1 | PYRAZINE-CONTAINING COMPOUND | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-11-26 | — | — | US | disclosed |
| US-10821109-B1 | Pyrazine-containing compound | CALCIMEDICA, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10821109-B1 | Pyrazine-containing compound | CALCIMEDICA, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180235958-A1 | PANCREATITIS TREATMENT | AVENUE CAPITAL MANAGEMENT II, L.P. | 2018-08-23 | — | — | US | disclosed |
| EP-3261641-A1 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| WO-2016138472-A1 | PANCREATITIS TREATMENT | CALCIMEDICA, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2012170931-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170931-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752148-B2 | Pyrazine-containing compound | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885NPC1 3259/4885 |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
| US-11013737-B2 | Pyrazine-containing compound | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885NPC1 3259/4885 |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | ORAI1, MAVS, CASR | STIM1 231/4885ORAI1 1/4885NPC1 3859/4885 |
| US-20220000863-A1 | PYRAZINE-CONTAINING COMPOUND | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885NPC1 3259/4885 |
| US-20220265645-A1 | PYRAZINE-CONTAINING COMPOUND | IAPP, NFATC1, NLRP3 | STIM1 213/4885ORAI1 6/4885NPC1 3316/4885 |
| US-20210038597-A1 | PYRAZINE-CONTAINING COMPOUND | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885NPC1 3259/4885 |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | IL1B, MAVS, MMP8 | STIM1 852/4885ORAI1 92/4885NPC1 4241/4885 |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | MAVS, ATF1, IL1B | STIM1 943/4885ORAI1 68/4885NPC1 4239/4885 |
| US-20230226058-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | CAMKK2, CAMKK1, ATF1 | STIM1 451/4885ORAI1 76/4885NPC1 3776/4885 |
| US-20200368228-A1 | PYRAZINE-CONTAINING COMPOUND | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885NPC1 3259/4885 |
| US-10821109-B1 | Pyrazine-containing compound | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885NPC1 3259/4885 |
| US-10973818-B2 | — | IAPP, NFATC1, PLA2R1 | STIM1 183/4885ORAI1 18/4885NPC1 2383/4885 |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885NPC1 262/4885 |
| US-11311535-B2 | Pancreatitis treatment | IAPP, PNLIP, VIP | STIM1 249/4885ORAI1 40/4885NPC1 2449/4885 |
| US-20180235958-A1 | PANCREATITIS TREATMENT | IAPP, PNLIP, VIP | STIM1 249/4885ORAI1 40/4885NPC1 2449/4885 |
| US-11439639-B2 | Pyrazine-containing compound | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885NPC1 3259/4885 |
| US-20240307384-A1 | PYRAZINE-CONTAINING COMPOUND | NFATC1, IAPP, NLRP3 | STIM1 211/4885ORAI1 5/4885NPC1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.